Risk-CAD: Risk-guided Disease Management in Coronary Artery Disease

Sponsor
Baker Heart and Diabetes Institute (Other)
Overall Status
Recruiting
CT.gov ID
NCT04966117
Collaborator
Heartwest (Other), University of Melbourne (Other), Queen's University, Belfast (Other), Western Health (Other)
270
1
2
29.5
9.2

Study Details

Study Description

Brief Summary

Coronary artery disease (CAD) is the number one killer of Australians with a high risk for a recurrent event(s) and hospital readmission. Many of these readmissions can be prevented with better management to control the problem of CAD. A disease management program, led by nurses who interact with other health professionals/providers, can help with education and counselling, taking medications correctly and making healthy lifestyle changes for higher risk patients. Newer models of disease management programs make use of mobile devices (such as an "app") and telehealth (by phone or video call) to monitor and manage health which could facilitate CAD management. Therefore, the aim of this study is to test this type of disease management program (DMP) compared to standard care for reducing hospital readmissions or death in people with CAD who are at high risk of being readmitted. The Investigators envisage that a novel Risk-Guided DMP will be favorable to patients and associated with high-level participation. The Investigators hypothesize that high-risk patients randomized to Risk-Guided CAD will have reduced hospital readmissions or death compared with those randomized to usual care.

Condition or Disease Intervention/Treatment Phase
  • Behavioral: Risk-Guided DMP
  • Behavioral: Usual Care
N/A

Detailed Description

The Investigators aim to test a nurse-led, technology-enabled model of health care delivery, called Risk-Guided DMP, to reduce readmissions following CAD, thereby enhancing recovery and survivorship.

The Investigators envisage that a novel Risk-Guided DMP will be favorable to patients and associated with high-level participation. The Investigators hypothesize reduced hospital readmissions or death for high-risk patients randomized to Risk-Guided DMP compared to usual care.

Methods

This proposed study is an effectiveness and feasibility trial of a risk guided DMP to reduce hospital readmissions in CAD patients. The Investigators seek to do this by adopting innovative approaches to:

  1. a community-based secondary prevention DMP, ii) supported by a novel m-Health app (SmartCR developed by CardiHab) to address components of a Cardiac Rehabilitation (CR) program, and
  2. selection of higher risk patients for appropriate management by validated (PEGASUS-TIMI
  1. criteria.

Patients aged 30-74 years who have been hospitalised with CAD will be recruited. Electronic medical records from Western Health (Sunshine or Footscray hospital) will be routinely screened (twice per week) to invite patients to participate. Heartwest cardiologists will also identify patients from their surgical lists.

Baseline measures will include clinical features (including severity and number of affected vessels) and biochemistry (troponin, B-type natriuretic protein, renal function) from medical records; patient self-reported socio-demographic features, cognitive function using the Montreal Cognitive Assessment as an important predictor of readmission, mental health via the Patient Health Questionnaire (PHQ-9) and Generalised Anxiety Disorder (GAD-7) questionnaire and quality of life using the Assessment of Quality of Life (AQoL-8D) questionnaire. Exercise capacity will be quantified by peak oxygen uptake (VO2 peak) and cardiac function will be assessed via two-dimensional echocardiography.

Risk evaluation will be performed by PEGASUS-TIMI 54 criteria for selection of high risk patients [score ≥5] who have an increased risk of a secondary event.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
270 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Intervention Model Description:
Single site, open, parallel-group randomized controlled trial of a disease management program (intervention group) to reduce hospital readmissions or death compared to usual care (control group)Single site, open, parallel-group randomized controlled trial of a disease management program (intervention group) to reduce hospital readmissions or death compared to usual care (control group)
Masking:
Single (Outcomes Assessor)
Masking Description:
There are no other parties who will be masked in the clinical trial.
Primary Purpose:
Prevention
Official Title:
A Risk-guided Disease Management and Tele-rehabilitation Program to Reduce Re-admissions in Coronary Artery Disease (Risk-Guided CAD)
Actual Study Start Date :
Jul 17, 2021
Anticipated Primary Completion Date :
May 31, 2023
Anticipated Study Completion Date :
Dec 31, 2023

Arms and Interventions

Arm Intervention/Treatment
Experimental: Risk-Guided DMP

The intervention is a 12 month disease management program after hospital discharge for coronary artery disease that is overseen by a cardiac nurse.

Behavioral: Risk-Guided DMP
Patients will be assigned a cardiac nurse to help manage their heart condition who will: develop a care plan and communicate with the patients' General Practitioner (GP) and cardiologist about management, particularly medications to help control risk factors. provide health coaching at pre-specified times over 12 months via telehealth (phone or video call) to ensure that patient's take their medications as prescribed and to give health education and guidance on lifestyle changes. facilitate cardiac rehabilitation via a smart phone or tablet app (called SmartCR). This app monitors health and physical activity, has prompted tasks to do and delivers education via video, audio and written articles. The information from this app can be used by the cardiac nurse during telehealth follow-up. invite participation to a supervised 6-week group exercise program which will require using our on-site gym.

Active Comparator: Usual Care

Usual care patients will receive standard cardiology care.

Behavioral: Usual Care
Usual care patients will receive standard cardiology care as scheduled that includes adherence to guideline-based care (medications and physical activity), education (self-care), a treatment plan to manage co-morbidities, early post-discharge follow-up/support and routine preventative care.

Outcome Measures

Primary Outcome Measures

  1. Hospitalization or death [90 days post discharge]

    Unplanned all-cause hospital readmission or death

Secondary Outcome Measures

  1. Hospitalization or death [30 days post discharge]

    Short term unplanned all-cause hospital readmission or death

  2. Provider adherence to best practice guidelines [12 months post discharge]

    Increased prescription of lipid-lowering, anti-hypertensive (e.g. beta-blocker) and antiplatelet agents

  3. Risk factor control - lipids [12 months post discharge]

    Change in LDL-cholesterol (mmol/L)

  4. Risk factor control - blood pressure [12 months post discharge]

    Change in systolic and diastolic blood pressure (mmHg)

  5. Health well-being [12 months post discharge]

    Change in quality of life (via AQoL-8D total scores and 8 dimension scores)

Other Outcome Measures

  1. Mobile Health (mHealth) engagement [12 months post discharge]

    SmartCR (cardiac rehabilitation app) will be evaluated by measures of app engagement by quantifying data entry events and other indicators of program participation/week

Eligibility Criteria

Criteria

Ages Eligible for Study:
30 Years to 74 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  1. Aged between 30 to 74 years; AND

  2. Hospitalised with CAD or other eligible cardiac procedure or condition including acute myocardial infarction (STEMI or NSTEMI), unstable angina, coronary artery bypass grafting or percutaneous coronary intervention; AND

  3. Defined as higher risk (score >= 5) by PEGASUS-TIMI 54 criteria; AND

  4. Eligible for Medicare.

Exclusion Criteria:
  1. Inability to provide written informed consent; OR

  2. Non-English speaking; OR

  3. Inability to attend clinic visits; OR

  4. Inability to engage with an app due to low technical literacy or lacking access to a smart phone or wi-fi; OR

  5. Hospitalised with a primary diagnosis of heart failure; OR

  6. eGFR <30 ml/min/1.73m2 (CKD stage 4 or stage 5); OR

  7. Valve disease only; OR

  8. Requiring palliative care; OR

  9. Concomitant terminal non-cardiac illnesses that could influence 12-month prognosis (e.g. advanced malignancy); OR

  10. Participating in another study with a potential but unknown effect on outcome.

Contacts and Locations

Locations

Site City State Country Postal Code
1 Baker Heart and Diabetes Institute Melbourne Victoria Australia 3004

Sponsors and Collaborators

  • Baker Heart and Diabetes Institute
  • Heartwest
  • University of Melbourne
  • Queen's University, Belfast
  • Western Health

Investigators

  • Principal Investigator: Melinda J Carrington, PhD, Baker Heart and Diabetes Institute

Study Documents (Full-Text)

More Information

Publications

None provided.
Responsible Party:
Baker Heart and Diabetes Institute
ClinicalTrials.gov Identifier:
NCT04966117
Other Study ID Numbers:
  • 266/21
First Posted:
Jul 19, 2021
Last Update Posted:
Mar 17, 2022
Last Verified:
Mar 1, 2022
Individual Participant Data (IPD) Sharing Statement:
Yes
Plan to Share IPD:
Yes
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by Baker Heart and Diabetes Institute
Additional relevant MeSH terms:

Study Results

No Results Posted as of Mar 17, 2022